Hot Stocks
15:01 EDT Plus Therapeutics presents data from Oongoing ReSPECT clinical trials - Plus Therapeutics presented data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome, in the treatment of recurrent glioblastoma and le The oral presentation, titled Safety and Feasibility of Rhenium-186 Nanoliposome in Leptomeningeal Metastases Phase 1/2a Dose Escalation Trial, demonstrated that the 186RNL dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1. Furthermore, all three patients in the cohort were observed to have prompt and complete 186RNL distribution throughout the cerebrospinal fluid subarachnoid space that was durable past one week and very well tolerated. Importantly, all patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 65% to 92% which was also durable. Another a poster titled, Safety and Feasibility of Rhenium-186 NanoLiposome in Recurrent Glioma: the ReSPECT Phase 1 Trial, demonstrated that in 23 subjects with recurrent GBM receiving a single administration of 186RNL, significant overall survival benefits were observed in those achieving an average absorbed radiation dose greater than 100 Gy to the tumor compared to those with less absorption. These findings suggest a correlation in increasing convected drug volume and radiation dose with improvement in overall survival of patients and to date, 80% of patients in cohorts 5-7 met the threshold of high levels of absorption greater than 100 Gy. Data show 186RNL treatment is safe and well-tolerated, with no adverse events with outcome of death or discontinuations. At the time of the presentation, four patients remain alive. Cohort 7 of the trial, with an increased dose of 186RNL, is currently enrolling.
|
